Savara Inc Long-term Line of Credit
Savara Inc (SVRA) had Long-term Line of Credit of $25.10 million as of 2020-12-31, per its 10-K filed 2021-03-10.
Discontinued › Balance Sheet › Liabilities
us-gaap:LineOfCredit · last filed 2021-03-10
- 2020-12-31: Long-term Line of Credit $25.10M.
- 2019-12-31: Long-term Line of Credit $25.11M.
- 2018-12-31: Long-term Line of Credit $24.53M.
- 2017-12-31: Long-term Line of Credit $14.78M.
| Period end | Long-term Line of Credit |
|---|---|
| 2020-12-31 | $25.10M 10-K · filed 2021-03-10 |
| 2019-12-31 | $25.11M 10-K · filed 2020-03-12 |
| 2018-12-31 | $24.53M 10-K · filed 2019-03-13 |
| 2017-12-31 | $14.78M 10-K · filed 2018-03-14 |
| 2016-12-31 | $3.83M 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |